Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Lapatinib-associated toxicity and practical management recommendations Moy B; Goss PEOncologist 2007[Jul]; 12 (7): 756-65Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.|Antineoplastic Agents/*adverse effects/therapeutic use[MESH]|Breast Neoplasms/*drug therapy/pathology[MESH]|Clinical Trials, Phase II as Topic[MESH]|Clinical Trials, Phase III as Topic[MESH]|Female[MESH]|Humans[MESH]|Lapatinib[MESH]|Neoplasm Recurrence, Local/drug therapy[MESH]|Protein Kinase Inhibitors/adverse effects/therapeutic use[MESH]|Quinazolines/*adverse effects/therapeutic use[MESH]|Receptor Protein-Tyrosine Kinases/antagonists & inhibitors[MESH]|Receptor, ErbB-2[MESH] |
